Physician profile
Benjamin Donner Willen
NPI 1437643905
$1,405.72
in general payments reported to CMS, 2019-2025
10 companies · $19.39 in 2025
The $19.39 reported for 2025 was less than what a typical Radiation Oncology provider received nationally (typical 2025 total: $172).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $125 · 2020: $23.11 · 2021: $449 · 2023: $364 · 2024: $425 · 2025: $19.39.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $458 · Grant: $350.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $458.40 |
| Grant | $350.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novocure INC. | $717.98 | 2019-2023 | Optune |
| Astrazeneca Pharmaceuticals LP | $380.27 | 2024 | Imfinzi |
| Progenics Pharmaceuticals, INC. | $103.25 | 2023 | Pylarify |
| Siemens Medical Solutions USA, INC. | $62.30 | 2023 | Bravos Afterloader System, Somatom Go.Top, Truebeam |
| Celgene Corporation | $44.68 | 2024 | Reblozyl |
| Janssen Biotech, INC. | $26.87 | 2023 | |
| Sumitomo Pharma America, INC. | $20.78 | 2023 | Orgovyx |
| Myriad Genetic Laboratories, INC. | $19.39 | 2025 | Prolaris |
| Novartis Pharmaceuticals Corporation | $15.55 | 2023 | |
| Elekta, INC. | $14.65 | 2023 | Elekta Medical Linear Accelerator |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Benjamin Willen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.